Article
Oncology
Eider Moreno-Cortes, Pedro Franco-Fuquen, Juan E. Garcia-Robledo, Jose Forero, Natalie Booth, Januario E. Castro
Summary: Anti-ROR1 CAR T-cells activated by ICOS.OX40 tandem co-stimulation show enhanced targeted cytotoxicity in vitro and in vivo, associated with a phenotype that promotes T-cell persistence.
FRONTIERS IN ONCOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Heather D. Ots, Jovanna A. Tracz, Katherine E. Vinokuroff, Alberto E. Musto
Summary: CD40-CD40L plays a key role in the central nervous system by upregulating proinflammatory molecules. Its function is well understood in the context of infection, but its role in neurological diseases of non-infectious etiology is unclear. This review examines the role of CD40-CD40L in various neurological diseases and highlights therapeutic advancements targeting the CD40 system.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Oncology
Ji-Eun Irene Yum, Young-Kwon Hong
Summary: VISTA is an emerging immune checkpoint molecule that plays a significant role in cancer progression by predominantly acting in an immune-suppressing manner. Ongoing clinical trials are investigating therapies targeting VISTA in various cancers.
FRONTIERS IN ONCOLOGY
(2021)
Article
Pharmacology & Pharmacy
Abdullahi Alausa, Khadijat Ayodeji Lawal, Oluwakemi Arinola Babatunde, E. N. O. Obiwulu, Olajumoke Christianah Oladokun, Olumide Samuel Fadahunsi, Ugwu Obiora Celestine, Emmanuel Ugbede Moses, Ifunanya Rejoice Akaniro, Peter Ifeoluwa Adegbola
Summary: The daily increase in new cases of pancreatic ductal adenocarcinoma is a divisive issue in cancer research. With a global cumulative case count of about 500,000, PDAC ranks as the fourteenth most common tumor in cancer research. It is also responsible for approximately 466,003 deaths annually, making it the seventh leading cause of cancer mortality. The lack of prominent symptoms in the early stages of PDAC has hindered efforts to develop an effective therapeutic agent against the disease. Recent immunotherapeutic research has turned to blocking checkpoint proteins as a management strategy for some cancers, specifically targeting the SIRP alpha-CD47 signaling cascade to prevent tumor regression. The concept of blocking this interaction to inhibit PDAC progression is currently under debate.
PHARMACOLOGICAL RESEARCH
(2022)
Review
Oncology
Nazli Dizman, Elizabeth I. Buchbinder
Summary: The review article discusses the role of the CD47/SIRPα axis in cancer, summarizes the efficacy and safety of therapeutics targeting CD47 or SIRPα, and explores the potential future implementation of these treatments for various cancer types.
Article
Biotechnology & Applied Microbiology
Qin-Hua Liu, Guan-Rong Dai, Xiao-Nan Wang, Lin Wang, Li-Li Li, Zheng-Sheng Wu, Rui-Xiang Xia
Summary: This study found that CDK12 was upregulated and miR-28-5p was downregulated in DLBCL. CDK12 knockdown or miR-28-5p overexpression could inhibit proliferation and promote apoptosis of DLBCL cells. CDK12 activated MYC to repress miR-28-5p/EZH2 and amplified tonic BCR signaling to promote the development of DLBCL.
CANCER GENE THERAPY
(2022)
Review
Immunology
George Fromm, Suresh de Silva, Taylor H. Schreiber
Summary: The extracellular domain of tumor necrosis factor receptors (TNFR) needs to assemble into a homotrimeric quaternary structure in order to initiate signaling. Synthetic agonists targeting TNF receptors have potential clinical benefits in amplifying immune responses, but their translation into human clinical studies has been limited and raised questions about the biology of TNF receptors.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Oncology
Anneloes van Duijn, Sjoerd H. Van der Burg, Ferenc A. Scheeren
Summary: This article focuses on the interactions between myeloid immune cells and anti-tumor immune responses in the tumor microenvironment. Blocking the CD47/SIRP alpha axis can enhance adaptive immune response. The potential therapeutic role of CD47/SIRP alpha axis is discussed in tumors with acquired resistance to classic immunotherapy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Review
Chemistry, Medicinal
Jorge Cebada, Martin Perez-Santos, Cindy Bandala, Eleazar Lara-Padilla, Irma Herrera-Camacho, Nora Hilda Rosas-Murrieta, Lourdes Millan-Perez Pena, Eduardo Monjaraz, Amira Flores, Maricruz Anaya-Ruiz
Summary: OX40 is an immune checkpoint associated with a good prognosis in cancer, making it a relevant target for new immunotherapy development. The patent literature analysis revealed an increasing trend in the development of OX40 agonists in cancer, particularly in the years 2018 and 2019. Major pharmaceutical companies such as AstraZeneca, Pfizer, GlaxoSmithKline, Bristol-Myers Squibb, and Roche have developed a majority of OX40 agonists in clinical trials.
EXPERT OPINION ON THERAPEUTIC PATENTS
(2021)
Article
Oncology
Ganggang Zhang, Bin Lan, Xin Zhang, Mengyao Lin, Yi Liu, Junsong Chen, Fang Guo
Summary: PD-1 and its ligand PD-L1 protect tumor cells from T cell-mediated killing. Understanding the regulatory mechanisms of PD-L1 expression can help develop more effective therapeutic strategies.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Dipti Thakkar, Shalini Paliwal, Bhushan Dharmadhikari, Siyu Guan, Lillian Liu, Shreya Kar, Nikhil K. Tulsian, Joshua J. Gruber, Leah DiMascio, Konrad H. Paszkiewicz, Piers J. Ingram, Jerome D. Boyd-Kirkup
Summary: This study developed the first Fc-independent anti-VISTA antibody HMBD-002, which reverses VISTA-induced immune suppression by blocking the functional domain of VISTA. The antibody has a neutralizing, non-depleting effect, effectively inhibiting tumor growth and enhancing T cell activity.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Chemistry, Multidisciplinary
Jingyue Yan, Yuebao Zhang, Shi Du, Xucheng Hou, Wenqing Li, Chunxi Zeng, Chengxiang Zhang, Jeffrey Cheng, Binbin Deng, David W. McComb, Weiyu Zhao, Yonger Xue, Diana D. Kang, Xiaolin Cheng, Yizhou Dong
Summary: A novel immunotherapy approach has been developed in this study, which enables co-stimulation of TLR7/8- and CD40-mediated pathways. By synthesizing and formulating RAL-LNPs, efficient delivery of CD40 mRNA to DCs was achieved both in vitro and in vivo. When combined with agonistic anti-CD40 antibody, this approach showed effective antitumor activities in mouse melanoma tumor models, establishing antitumor memory immunity.
ADVANCED MATERIALS
(2022)
Article
Oncology
M. J. Melake, H. G. Smith, D. Mansfield, E. Davies, M. T. Dillon, A. C. Wilkins, E. C. Patin, M. Pedersen, R. Buus, A. A. Melcher, K. Thway, A. B. Miah, S. H. Zaidi, A. J. Hayes, T. R. Fenton, K. J. Harrington, M. McLaughlin
Summary: This study explores the immune contexture of sarcoma and identifies potential therapeutic targets using genomics and immunohistochemistry. The findings suggest that radioresistant sarcoma subtypes have higher transcript levels of immunotherapy targets. The study also reveals that 4-1BB and other costimulatory molecules can delineate distinct tumor immune profiles. Additionally, spatial analysis identifies a specific type of OX40+ regulatory T cells associated with tertiary lymphoid structures in sarcoma. These findings contribute to the understanding of sarcoma immunology and provide important insights for patient stratification and immunotherapies.
Review
Biotechnology & Applied Microbiology
Haiqin Liao, Chengcheng Niu
Summary: This article introduces the mechanisms by which cancer evades immunological surveillance and the CD47-SIRPα signaling pathway, as well as the applications of nanocarriers developed for this signaling pathway in anticancer treatment.
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY
(2022)
Review
Oncology
Renee Bouwstra, Tom van Meerten, Edwin Bremer
Summary: The CD47-SIRP alpha 'don't eat me' signaling axis is a prominent innate immune checkpoint, but monotherapy has limited therapeutic effect and severe side effects. Promising clinical responses have been seen with combination therapy, but toxicity issues remain. Innovations include novel antibody formats targeting CD47 on tumor cells and tumor-targeted bispecific antibodies. Combinatorial approaches with opsonizing antibodies, systemic therapy, epigenetic drugs, T-cell-targeted therapeutics, or dual immunomodulatory CD47 bispecific antibodies aim to improve the therapeutic effect of CD47 blockade.
CLINICAL AND TRANSLATIONAL MEDICINE
(2022)
Article
Biochemistry & Molecular Biology
Gaber Ali, Hany Omar, Fatema Hersi, Amira Abo-Youssef, Osama Ahmed, Wafaa Mohamed
Summary: This study aimed to investigate the chemopreventive effect of etoricoxib on DENA/2AAF-induced HCC in male Wistar rats. The results demonstrated that etoricoxib possesses an anticancer effect through its antioxidant, anti-inflammatory, and modulation of NF-KB/COX-2/PGE2 signaling.
CURRENT MOLECULAR PHARMACOLOGY
(2022)
Review
Oncology
Nada K. Sedky, Alyaa A. Hamdan, Salma Emad, Aya L. Allam, Mohamed Ali, Mai F. Tolba
Summary: Solid tumors, such as skin, lung, breast, colon, and prostate cancers, pose a significant challenge in treatment, especially in advanced/metastatic cases. Targeting the PD-1/PD-L1 immune checkpoint has been studied extensively as a new approach to managing these hard-to-treat cancers. However, monotherapy with immunotherapies has shown low response rates and resistance, necessitating the development of combination regimens with other immune modulatory agents. Epigenetic modifiers, such as HDACIs, have shown promising effects in modulating the tumor microenvironment and host immune cells, making them attractive candidates for combination testing with immunotherapy.
CLINICAL & TRANSLATIONAL ONCOLOGY
(2022)
Article
Pharmacology & Pharmacy
Christine N. Habib, Mohamed R. Mohamed, Mariane G. Tadros, Mai F. Tolba, Esther T. Menze, Somia Masoud
Summary: The study found that diosmin (DM) has neuroprotective effects in Parkinson's disease (PD) and can act through various mechanisms such as anti-inflammatory and antioxidative properties. These findings suggest that DM may be a promising candidate for managing the neuropathological course of PD.
EUROPEAN JOURNAL OF PHARMACOLOGY
(2022)
Article
Medicine, Research & Experimental
Fatema Hersi, Sara M. Elgendy, Salma A. Al Shamma, Roa T. Altell, Omar Sadiek, Hany A. Omar
Summary: The landscape of cancer therapy has been transformed by immune checkpoint inhibitors (ICIs) which improved patient survival. However, the unpredictability and adverse effects of patient response to these therapies pose challenges. The composition of gut microbiota, particularly microbiota-derived metabolites like short-chain fatty acids, plays a crucial role in modulating patient sensitivity to cancer immunotherapy.
Article
Biochemistry & Molecular Biology
Reinad R. Abu Rabah, Anusha Sebastian, Srinivasulu Vunnam, Shaista Sultan, Hamadeh Tarazi, Hanan S. Anbar, Mahmoud K. Shehata, Seyed-Omar Zaraei, Sara M. Elgendy, Salma A. Al Shamma, Hany A. Omar, Taleb H. Al-Tel, Mohammed El-Gamal
Summary: The study reports on a new series of pyrazole derivatives with potential anticancer activity. Compound 1f showed the most potent anticancer activity against various cancer cell lines, even more potent than sorafenib and SP600125. Compounds 1b, 1c, and 1h demonstrated strong anti-proliferative activity against hepatocellular carcinoma cell lines. The study also discovered two potent JNK3 inhibitors, compounds 1c and 1f, with good inhibitory effects in whole-cell assays.
BIOORGANIC & MEDICINAL CHEMISTRY
(2022)
Article
Biochemistry & Molecular Biology
Kholoud Y. Abushawish, Sameh S. M. Soliman, Alexander D. Giddey, Hamza M. Al-Hroub, Muath Mousa, Karem H. Alzoubi, Waseem El-Huneidi, Eman Abu-Gharbieh, Sara M. Elgendy, Yasser Bustanji, Nelson C. Soares, Mohammad H. Semreen
Summary: This study investigated the proteomic and metabolomics alterations associated with sorafenib resistance in hepatocellular carcinoma cells. The findings identified potential biomarkers for sorafenib-resistant HCC and provided insights into their role in chemotherapeutic drug resistance, cancer progression, and aggressiveness.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Medicine, Research & Experimental
Dima W. Alhamad, Sara M. Elgendy, Fatema Hersi, Hesham R. El-Seedi, Hany A. Omar
Summary: The study found differences in autophagy regulation in resistant hepatocellular carcinoma cells, and demonstrated that the combination of an autophagy inhibitor and a chemotherapeutic agent can promote cell death, reduce drug resistance, and increase reactive oxygen species production and apoptosis induction.
Article
Medicine, Research & Experimental
Razan B. Al-Humaidi, Bahgat Fayed, Sarra B. Shakartalla, Jayalakshmi Jagal, Manju N. Jayakumar, Zainab M. Al Shareef, Suleiman I. Sharif, Ayman Noreddin, Mohammad H. Semreen, Hany A. Omar, Mohamed Haider, Sameh S. M. Soliman
Summary: Breast cancer is a common harmful disease in women, and its treatment remains a challenge. Research shows that blocking macropinocytosis in MCF-7 cells can inhibit cancer progression without harming normal cells. However, caution is needed to address the potential nutrient deprivation and metastatic activity caused by macropinocytosis.
Article
Chemistry, Medicinal
Mohamed A. Abdelgawad, Syed N. A. Bukhari, Arafa Musa, Mohammed Elmowafy, Mohammed H. Elkomy, AbdElAziz A. Nayl, Ahmed H. El-Ghorab, Ibrahim Hotan Alsohaimi, Mohamed Sadek Abdel-Bakky, Ibrahim O. Althobaiti, Hamud A. Altaleb, Hany A. Omar, Ahmed H. Abdelazeem, Mohamed A. Zaki, Mohamed E. Shaker, Heba A. H. Elshemy
Summary: This study designed and synthesized new sulphamethoxazole derivatives and evaluated their inhibitory activities against human carbonic anhydrase IX and XII, revealing that compound S15 may serve as a potential lead for emerging selective cytotoxic compounds targeting hCAs IX and XII.
Article
Biochemistry & Molecular Biology
Mohamed A. Abdelgawad, Syed Nasir Abbas Bukhari, Arafa Musa, Mohammed Elmowafy, AbdElAziz A. Nayl, Ahmed H. El-Ghorab, Mohamed Sadek Abdel-Bakky, Hany A. Omar, Nasser Hadal Alotaibi, Hossam M. Hassan, Mohammed M. Ghoneim, Rania B. Bakr
Summary: New phthalazone tethered 1,2,3-triazole derivatives 12-21 were synthesized through Cu(I)-catalyzed click reactions. The synthesized compounds were confirmed by spectroscopic tools and elemental analysis. The antiproliferative efficacy of compounds 12-21 against cancer cell lines was evaluated, and compound 16 showed potent activity and selectivity. In silico molecular docking confirmed stable protein-ligand interactions for the effective derivatives.
BIOORGANIC CHEMISTRY
(2023)
Article
Medicine, Research & Experimental
Salma A. Al-Shamma, Dana M. Zaher, Fatema Hersi, Nour N. Abu Jayab, Hany A. Omar
Summary: Modern cancer chemotherapy has been limited by the resistance of cancer cells to therapy. One crucial factor in chemotherapy resistance is the overexpression of ALDH, which detoxifies toxic aldehydes and prevents the formation of reactive oxygen species. This review discusses the mechanisms of chemotherapy resistance promoted by ALDH and highlights its role in cancer stemness, metastasis, metabolism, and cell death. Targeting ALDH in combination with other treatments may be a potential therapeutic strategy to overcome resistance in various cancers.
Editorial Material
Pharmacology & Pharmacy
Husain Yar Khan, Khuloud Bajbouj, Mai F. Tolba
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Pharmacology & Pharmacy
Mohammed H. Elkomy, Fatma I. Abo El-Ela, Randa Mohammed Zaki, Omar A. Alsaidan, Mohammed Elmowafy, Ameeduzzafar Zafar, Khaled Shalaby, Mohamed A. Abdelgawad, Hany A. Omar, Rania Salama, Hussein M. Eid
Summary: This study developed and optimized a drug-loaded thermosensitive gel for intranasal administration to combat depression. The results demonstrated that compared to other formulations, this thermosensitive gel significantly improved behavioral performance and alleviated neural tissue changes in depressed rats. Further research is needed to determine its effectiveness in humans.
Article
Pharmacology & Pharmacy
Hanan S. Anbar, Nisha Yarifbhai Vahora, Hajra laghman Shah, Mariyam Mohammed Azam, Tamanna Islam, Fatima Hersi, Hany A. Omar, Wolfgang Dohle, Barry V. L. Potter, Mohammed I. El-Gamal
Summary: This study investigated the therapeutic potential of three drug candidates for the treatment of PCOS. The drug candidates showed promising effects on ovarian and uterine weight, lipid profile, hormone levels, and signaling pathways.
EUROPEAN JOURNAL OF PHARMACOLOGY
(2023)
Article
Multidisciplinary Sciences
Adeniyi Francis Fagbamigbe, Mai F. Tolba, Ebenezer F. Amankwaa, Priscilla Kolibea Mante, Augustina Angelina Sylverken, Julien Z. B. Zahouli, Nowsheen Goonoo, Lydia Mosi, Kolapo Oyebola, Damaris Matoke-Muhia, Dziedzom K. de Souza, Kingsley Badu, Natisha Dukhi
Summary: This article assesses the realities and pros and cons of the WHO COVID-19 interim guidance in Africa and discusses the known peculiarities of the continent. The findings provide important links between sub-themes that may impact the containment and management of COVID-19 cases in Africa.
SCIENTIFIC AFRICAN
(2022)
Review
Oncology
Rui Wang, Aashiq Hussain, Quanquan Guo, Meimei Ma
Summary: DNA is highly immunogenic and can activate the cGAS-STING pathway, which plays a crucial role in the pathogenesis and progression of neoplastic diseases. The modulation of cGAS-STING signaling holds great promise for cancer therapy, although there are disagreements on whether to activate or inhibit this pathway.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2024)
Review
Oncology
Ali Zarezadeh Mehrabadi, Faezeh Shahba, Hossein Khorramdelazad, Nazanin Aghamohammadi, Milad Karimi, Kowsar Bagherzadeh, Majid Khoshmirsafa, Ramin Massoumi, Reza Falak
Summary: IL-1 receptor accessory protein (IL-1RAP) plays a crucial role in inflammatory conditions and tumorigenesis in the tumor microenvironment. It is involved in the progression, metastasis, and angiogenesis of solid tumors and hematological malignancies.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2024)
Review
Oncology
Xiao Tang, Yujie Niu, Jinli Jian, Yuancheng Guo, Yin Wang, Yu Zhu, Bei Liu
Summary: Ferroptosis is an iron-dependent form of cell death that promotes tumor cell death by causing cell membrane rupture and accumulation of lipid peroxides. Extensive research has been conducted to explore the mechanism of ferroptosis inducers, but its role in hematological tumors is still limited.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2024)
Review
Oncology
Tanwei Yuan, Dominic Edelmann, Jakob N. Kather, Ziwen Fan, Katrin E. Tagscherer, Wilfried Roth, Melanie Bewerunge-Hudler, Alexander Brobeil, Matthias Kloor, Hendrik Blaeker, Barbara Burwinkel, Hermann Brenner, Michael Hoffmeister
Summary: The study aimed to analyze and validate previously published CpG-methylation-based prognostic biomarkers and prediction models for colorectal cancer (CRC) prognosis. The results showed that the discrimination ability of the models was insufficient and lacked clinical relevance.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2024)
Review
Oncology
Zhihui Duan, Dandan Yang, Ping Yuan, Xiaoming Dai, Guodong Chen, Daichao Wu
Summary: This article provides a comprehensive overview of therapeutic cancer vaccines, including their classification, clinical application, efficacy, and combination strategies with other therapies. It offers a valuable theoretical basis for the future clinical application and development of therapeutic cancer vaccines.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2024)